NextCure Inc (NASDAQ:NXTC) Receives Consensus Recommendation of “Strong Buy” from Brokerages
Shares of NextCure Inc (NASDAQ:NXTC) have earned an average broker rating score of 1.17 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and two have issued a strong buy rating on the company.
Brokerages have set a 12-month consensus target price of $25.33 for the company and are forecasting that the company will post ($0.47) earnings per share for the current quarter, according to Zacks. Zacks has also assigned NextCure an industry rank of 53 out of 256 based on the ratings given to related companies.
A number of analysts have recently commented on NXTC shares. Bank of America restated a “buy” rating and set a $43.00 price objective (up from $36.00) on shares of The Medicines in a report on Tuesday, July 9th. Piper Jaffray Companies downgraded Cypress Semiconductor from an “overweight” rating to a “neutral” rating in a report on Monday, June 3rd. Finally, Morgan Stanley downgraded Meili from an “equal weight” rating to an “underweight” rating and dropped their price objective for the stock from $14.00 to $4.20 in a report on Monday, June 3rd.
NXTC stock opened at $16.78 on Tuesday. The business’s fifty day moving average price is $16.57. NextCure has a 52 week low of $13.86 and a 52 week high of $22.75.
NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Monday, June 10th. The company reported ($4.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($3.93). The firm had revenue of $1.36 million during the quarter. Research analysts predict that NextCure will post -2.08 earnings per share for the current year.
NextCure Company Profile
There is no company description available for NextCure Inc
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.